| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P < 0·05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.
This article has been cited by other articles:
|
|
 |
|
  H. Otani, F. Otsuka, K. Inagaki, J. Suzuki, T. Miyoshi, Y. Kano, J. Goto, T. Ogura, and H. Makino Aldosterone Breakthrough Caused by Chronic Blockage of Angiotensin II Type 1 Receptors in Human Adrenocortical Cells: Possible Involvement of Bone Morphogenetic Protein-6 Actions Endocrinology, June 1, 2008; 149(6): 2816 - 2825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Enomoto, M Yoshiyama, T Omura, R Matsumoto, T Kusuyama, S Kim, Y Izumi, K Akioka, H Iwao, K Takeuchi, et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction Heart, December 1, 2005; 91(12): 1595 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Ravis, S. Reid, D. A. Sica, and D. S. Tolbert Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal Impairment J. Clin. Pharmacol., July 1, 2005; 45(7): 810 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J Barnes and P. A Howard Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure Ann. Pharmacother., January 1, 2005; 39(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Connell Review: Aldosterone -- the future challenge in cardiovascular disease? The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 370 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. McCurley, S. U. Hanlon, S.-k. Wei, E. F. Wedam, M. Michalski, and M. C. Haigney Furosemide and the progression of left ventricular dysfunction in experimental heart failure J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]
|
|
|
|
|
|
A. D Struthers Aldosterone blockade in heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S23 - S27. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Epstein Aldosterone receptor blockade and the role of eplerenone: evolving perspectives Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1984 - 1992. [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Cohn, I. S. Anand, R. Latini, S. Masson, Y.-T. Chiang, and R. Glazer Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial Circulation, September 16, 2003; 108(11): 1306 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, S. K Hildemann, P. Tas, G. Ertl, and J. Bauersachs Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction Cardiovasc Res, June 1, 2003; 58(3): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Eplerenone: Cardiovascular Protection Circulation, May 20, 2003; 107(19): 2512 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sato, K. Hayashi, M. Naruse, and T. Saruta Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy Hypertension, January 1, 2003; 41(1): 64 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Suzuki, H. Morita, T. Mishima, V. G. Sharov, A. Todor, E. J. Tanhehco, A. E. Rudolph, E. G. McMahon, S. Goldstein, and H. N. Sabbah Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure Circulation, December 3, 2002; 106(23): 2967 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Cook, L. M. Berry, D. H. Kim, E. G. Burton, J. D. Hribar, and L. Zhang Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5 Drug Metab. Dispos., December 1, 2002; 30(12): 1344 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Soler-Soler and D. Garcia-Dorado How to best to counteract the enemies? By blocking neurohormonal activation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G45 - G50. [Abstract] [PDF]
|
|
|
|
|
|
M. Naruse, A. Tanabe, A. Sato, S. Takagi, K. Tsuchiya, T. Imaki, and K. Takano Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, July 1, 2002; 40(1): 28 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ferrara, F Mastrorilli, G Pasanisi, S Censi, N D'aiello, A Fucili, M Valgimigli, and R Ferrari Neurohormonal modulation in chronic heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D3 - D11. [Abstract] [PDF]
|
|
|
|
|
|
J. Bauersachs, M. Heck, D. Fraccarollo, S. K. Hildemann, G. Ertl, M. Wehling, and M. Christ Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression J. Am. Coll. Cardiol., January 16, 2002; 39(2): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Takaya, T. Matsusaka, H. Katori, M. Tamura, Y. Miyazaki, T. Homma, and I. Ichikawa In Situ Demonstration of Angiotensin-Dependent and Independent Pathways for Hyperaldosteronism During Chronic Extracellular Fluid Volume Depletion Mol. Endocrinol., December 1, 2001; 15(12): 2229 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force for the Diagnosis and Treatment of Chro, W. J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure Eur. Heart J., September 1, 2001; 22(17): 1527 - 1560. [PDF]
|
|
|
|
|
|
K.-M. Yee, S. D. Pringle, and A. D. Struthers Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1800 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Sanoski The Year in Review: Cardiology Journal of Pharmacy Practice, February 1, 2001; 14(1): 18 - 40. [Abstract] [PDF]
|
|
|
|
|
|
J. Bauersachs, D. Fraccarollo, G. Ertl, N. Gretz, M. Wehling, and M. Christ Striking Increase of Natriuresis by Low-Dose Spironolactone in Congestive Heart Failure Only in Combination With ACE Inhibition : Mechanistic Evidence to Support RALES Circulation, November 7, 2000; 102(19): 2325 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, and The Randomized Aldactone Evaluation Study Investig The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure N. Engl. J. Med., September 2, 1999; 341(10): 709 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Coodley Newer Drug Therapy for Congestive Heart Failure Arch Intern Med, June 14, 1999; 159(11): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, P. N. Chander, A. Zuckerman, and C. T. Stier Jr. Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1999; 33(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
